WSE:BLR

Stock Analysis Report

Executive Summary

BLIRT S.A., a biotechnology company, focuses on the production of specialty enzymes utilized in nucleic acid purification and sequencing in Poland.

Rewards

PE ratio (14.1x) is below the Biotechs industry average (29.2x)

Became profitable this year

Risk Analysis

Does not have a meaningful market cap (PLN20M)

Highly volatile share price over past 3 months

Does not have meaningful revenue (PLN11M)



Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has BLIRT's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

4.8%

BLR

-3.9%

PL Biotechs

-2.6%

PL Market


1 Year Return

59.4%

BLR

-20.1%

PL Biotechs

-7.7%

PL Market

Return vs Industry: BLR exceeded the Polish Biotechs industry which returned -20.1% over the past year.

Return vs Market: BLR exceeded the Polish Market which returned -7.7% over the past year.


Shareholder returns

BLRIndustryMarket
7 Day4.8%-3.9%-2.6%
30 Day19.6%-7.0%-6.0%
90 Dayn/a-16.2%-1.4%
1 Year59.4%59.4%-19.9%-20.1%-4.8%-7.7%
3 Year-45.0%-45.0%-49.1%-49.1%5.5%-2.2%
5 Year-37.1%-37.1%-16.9%-18.9%0.2%-12.2%

Price Volatility Vs. Market

How volatile is BLIRT's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BLIRT undervalued compared to its fair value and its price relative to the market?

14.13x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BLR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BLR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BLR is good value based on its PE Ratio (14.1x) compared to the Biotechs industry average (29.2x).

PE vs Market: BLR is poor value based on its PE Ratio (14.1x) compared to the Polish market (10.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BLR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BLR is good value based on its PB Ratio (2.2x) compared to the PL Biotechs industry average (2.2x).


Next Steps

Future Growth

How is BLIRT forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

15.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIRT has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has BLIRT performed over the past 5 years?

4.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLR has high quality earnings.

Growing Profit Margin: BLR became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BLR has become profitable over the past 5 years, growing earnings by 4.2% per year.

Accelerating Growth: BLR has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BLR has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: BLR's Return on Equity (15.9%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is BLIRT's financial position?


Financial Position Analysis

Short Term Liabilities: BLR's short term assets (PLN6.4M) exceed its short term liabilities (PLN1.0M).

Long Term Liabilities: BLR's short term assets (PLN6.4M) exceed its long term liabilities (PLN239.0K).


Debt to Equity History and Analysis

Debt Level: BLR is debt free.

Reducing Debt: BLR currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: BLR has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BLR has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: BLR has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BLR's debt is covered by short term assets.


Next Steps

Dividend

What is BLIRT's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.6%markettop25%7.3%industryaverage1.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate BLR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BLR's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLR's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

What is the CEO of BLIRT's salary, the management and board of directors tenure and is there insider trading?


CEO

Marian Popinigis 0

1.4yrs

Tenure

0

Mr. Marian Popinigis has been the Chief Executive Officer at BLIRT S.A. since July 2018. Mr. Popinigis is a Co-Founder of Mercor S.A. and serves as its Chairman, President and General Director. Mr. Popinig ...


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Marian Popinigis

    Vice President of the Management Board & CEO

    • Tenure: 1.4yrs
  • Jerzy Milewski

    President of the Management Board

    • Tenure: 0yrs
  • Pawel Olszewski

    Head of Analytical Department

    • Tenure: 0yrs
  • Witold Grabysz

    Vice President of the Management Board and Vice President

    • Tenure: 0yrs
  • Tomasz Wrzesinski

    Managing Director of Marketing & Sales

    • Tenure: 1.4yrs

Board Members

  • Józef Kur

    Chairman of Supervisory Board

    • Tenure: 0yrs
  • Waclaw Szybalski

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Aleksander Wlezieñ

    Member of Supervisory Board

    • Tenure: 0yrs
  • Wenanty Plichta

    Vice Chairman of Supervisory Board

    • Tenure: 0yrs
  • Jacek Milewski

    Member of Supervisory Board

    • Tenure: 0yrs
  • Ryszard Andruszkiewicz

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Rafal Dziadziuszko

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Andrzej Skladanowski

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Boguslaw Szewczyk

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

BLIRT S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BLIRT S.A.
  • Ticker: BLR
  • Exchange: WSE
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł19.604m
  • Shares outstanding: 17.20m
  • Website: https://www.blirt.eu

Location

  • BLIRT S.A.
  • Trzy Lipy 3/1.38
  • Gdansk
  • 80-172
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLRWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNMar 2011

Biography

BLIRT S.A., a biotechnology company, focuses on the production of specialty enzymes utilized in nucleic acid purification and sequencing in Poland. The company offers a suite of services, including the des ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/07 21:25
End of Day Share Price2019/12/05 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.